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was their use of antidiabetic medications in the 90 days prior to
their HbA1c test. All results are descriptive in nature. RESULTS:
A majority of the patient population was male in their mid-60.
Hypertension (51%) and ischemic heart disease (19%) were
commonly diagnosed co-morbidities. Of patients with type-2
diabetes, 30% received no antidiabetic medications, 41% were
treated with a single antidiabetic agent (e.g., metformin, sul-
fonylurea), while the remaining patients received combination
therapy. Over half of the patients who received some antidiabetic
medication had an HbA1c that did not meet the NICE recom-
mendation of 7.5% or less. Interestingly, more than 70% of the
patients who received either insulin alone or in combination with
oral antidiabetic medications (s) had HbA1c values greater than
7.5%. CONCLUSIONS: Despite recent important advances in
pharmacotherapy for type-2 diabetes, glycemic control remains
suboptimal for a large percentage of patients in the UK. In order
to adhere to NICE recommendations, health care professionals
may wish to consider further additive or alternative treatment
options.
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OBJECTIVE: The link between clinical responses to treatment
and changes in the Dermatology Life Quality Index (DLQI) has
not been established in moderate to severe plaque psoriasis. The
objective of this study was to determine changes in DLQI total
score that correlate with clinical improvement in this patient
group treated with adalimumab. METHODS: A randomized,
double-blind, placebo-controlled, multi-center clinical trial for
the treatment of moderate to severe plaque psoriasis with adal-
imumab was conducted. Patients (n = 147) were randomized to
adalimumab 40mg every other week (eow), adalimumab 40mg
weekly, or placebo, and were followed for up to 12 weeks. The
correlation between changes in the DLQI total score and clini-
cal assessment of psoriasis severity, using the Psoriasis Area and
Severity Index (PASI), was evaluated. To determine a minimum
clinically important difference (MCID) for DLQI total score, a
change of between 25% and 49% in the PASI score was used.
Three standard distributional methods were used to determine
the MCID for DLQI total score. RESULTS: The MCID for DLQI
total score ranged from 2.3 to 4.0. This represents changes in
dermatologic functional limitations in patients who achieved at
least a 25% improvement in PASI score. In patients who had
achieved at least a 75% improvement in PASI score, mean
improvement in DLQI total score was 10.8 points in patients
randomized to adalimumab 40mg eow, 11.5 points in those who
had received adalimumab 40mg weekly, and only 1.3 points in
the placebo group. CONCLUSION: The MCID for DLQI total
score established in this study was between 2.3 to 4.0. Given that
adalimumab-treated patients experienced a mean change in
DLQI of at least 10 points, improvement in dermatologic-related
functional limitations with this treatment is likely above the
MCID.
QL6
ADALIMUMAB REDUCES FATIGUE IN PATIENTS WITH
ACTIVE ANKYLOSING SPONDYLITIS (AS)—6-MONTH
RESULTS OF A CANADIAN AS STUDY
Luo MP1, Revicki D2, Rentz A2,Wong RL3, Maksymowych WP4
1Abbott Laboratories, Abbott Park, IL, USA; 2MEDTAP Institute at
United Biosource Corporation, Bethesda, MD, USA; 3Abbott
Laboratories, Parsippany, NJ, USA; 4University of Alberta Hospital,
Edmonton, AB, Canada
OBJECTIVES: Fatigue is a common, distressing symptom of
ankylosing spondylitis (AS), a chronic inﬂammatory disease pre-
dominantly affecting the spine. This study evaluated whether
adalimumab therapy reduced fatigue in patients with active AS.
METHODS: A randomized, placebo-controlled, Phase III study
of adalimumab was conducted in Canada with patients with
active AS who had experienced an inadequate response to at 
least one NSAID or disease-modifying, antirheumatic drug
(DMARD). Patients received either adalimumab 40mg every
other week or placebo for 24 weeks. Fatigue was assessed by the
Functional Assessment of Chronic Illness Therapy-Fatigue
(FACIT-F), a widely used measure of fatigue in chronic illnesses,
and the fatigue item of the BATH AS Disease Activity Index
(BASDAI), a well-established instrument used in clinical studies
to evaluate AS disease activity. FACIT-F scores range from 0–52,
with higher scores representing less fatigue, and a >= 3-point
change considered clinical meaningful. The BASDAI fatigue item
ranges from 0–10, with lower scores reﬂecting less fatigue.
RESULTS: A total of 82 patients (38 on adalimumab, 44 on
placebo) were enrolled. At baseline, both arms had comparable
demographics and disease characteristics. Baseline FACIT-F
(adalimumab 24.4, placebo 23.6) and BASDAI fatigue (adali-
mumab 6.3, placebo 6.9,) were similar between arms. After 12
weeks, adalimumab patients had achieved statistically signiﬁ-
cantly greater improvement in FACIT-F than placebo patients
(6.9 vs. 1.7, p = 0.005). In addition, patients on adalimumab had
achieved statistically greater improvement in BASDAI fatigue vs.
placebo (-1.7 vs. -0.5, p = 0.006). Even greater improvements
were achieved at 24 weeks in adalimumab vs. placebo patients
for both measures (FACIT-F, 7.8 vs. 2.6, p = 0.013, and BASDAI
fatigue, -1.9 vs. -0.5, p = 0.006). Improvements in FACIT-F at
both 12 and 24 weeks were clinical meaningful. CONCLU-
SIONS: These results indicate adalimumab treatment provides
AS patients with statistically signiﬁcant and clinically meaning-
ful improvements in fatigue compared with placebo.
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OBJECTIVES: To describe the observed changes in quality of life
and bother associated with LUTS at one year from baseline
assessment in a sample of Italian women. METHODS: The
FLOW study is a two-year observational investigation aimed at
evaluating prevalence, clinical progression and QoL impact of
female LUTS. Women aged ≥ 18 years, not pregnant, with LUTS
for ≥3 months and negative dipstick were consecutively enrolled
in 39 Italian Urology Centres. Symptoms and QoL were assessed
by: ICIQ-LF, W-IPSS and SF-36. Differences between the ques-
tionnaires’ scores at baseline and follow-up visits were calculated
to assess deterioration or improvement in QoL. Here we refer to
